COMMUNIQUÉS West-GlobeNewswire

Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates
04/09/2025
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates Compelling kidney function data and meta-analysis from two Phase 2 studies, VIVIAD and VIVA-MIND, presented in oral presentation at ERA [...]
Kuros Biosciences announces changes in the Board of Directors
04/09/2025
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences announces changes in the Board of Directors Schlieren (Zurich), Switzerland, September 4, 2025 – Kuros Biosciences (“Kuros” or the “ [...]
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique
04/09/2025
L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab, [...]
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
04/09/2025
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated [...]
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique
04/09/2025
L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab, [...]
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
04/09/2025
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated [...]
Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entier
04/09/2025
Communiqué de presse Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entier La Société prévoit de rembourser intégralement les dettes financières [...]
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
04/09/2025
Press Release Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026 NCX 470 NDA submissions in U.S. (H1 2026) and [...]
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
04/09/2025
MINNEAPOLIS and BRISBANE, Australia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to designing, [...]
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
04/09/2025
Susvimo is under review with the EMA and once approved will be the first continuous delivery treatment for nAMD, affecting 1,7 million in the European Union 1 New seven-year data from the LADDER study show Contivue with [...]
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
04/09/2025
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO [...]
Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases
04/09/2025
O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases Clinical Trial Application approval marks Onco3R’s [...]
Lygos Clinic Launches VIP All-Inclusive Dental Tourism Packages for International Patients
04/09/2025
ISTANBUL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lygos Clinic, a leading dental center in Istanbul, has officially launched its new VIP all-inclusive dental tourism packages , designed to meet the rising global demand for [...]
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
04/09/2025
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of [...]
JUST ON SLEEP Officially Launches on Shopee Singapore, Redefining Sleep Safety and Wellness
04/09/2025
SINGAPORE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- JUST ON SLEEP, a smart contactless sleep monitoring device developed by Sewon Intelligence, has recently launched in Singapore via Shopee, making advanced sleep wellness and [...]
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
04/09/2025
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/09/2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/09/2025
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
03/09/2025
ZUG, Switzerland, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' [...]

Pages